Arteriovenous Fistula
Conditions
Keywords
(AVF), surgery
Brief summary
The investigators designed a prospective randomized study to compare the conventionally used sedative drug propofol with a latest alternative dexmedetomidine (DEX), in patients with end-stage renal disease undergoing arteriovenous fistula (AVF) surgery.
Interventions
DRUGPropofol
Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).
DRUGDexmedetomidine
DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).
Sponsors
Baskent University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Inclusion criteria were patients undergoing arteriovenous fistula (AVF) surgery aged between 20-70 with end stage renal failure on dialysis treatment.
Exclusion criteria
*
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of adverse effects such as respiratory and hemodynamic events | up to 24 hours postoperative |
Secondary
| Measure | Time frame |
|---|---|
| The sedation onset time with using BIS and recovery times during the procedure. | up to 24 hours postoperative |
Countries
Turkey (Türkiye)
Contacts
Primary ContactOzlem Ozmete, MD
Backup ContactCagla Bali, MD
Outcome results
None listed